利伐沙班片致胆固醇结晶栓塞的病例分析  

Case report of cholesterol crystal embolism caused by rivaroxaban tablets

作　　者：李瑞娟 向倩[1] 崔一民[1] LI Rui-juan;XIANG Qian;CUI Yi-min(Department of Pharmacy,Peking University First Hospital,Bejing 100034,China;Department of Pharmacy,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Third Hospital of Shanxi Medical University,Taiyuan 030032,Shanxi Province,China;Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei Province,China)

机构地区：[1]北京大学第一医院药学部,北京100034 [2]山西白求恩医院、山西医学科学院同济山西医院、山西医科大学第三医院药学部,山西太原030032 [3]华中科技大学同济医学院附属同济医院药学部,湖北武汉430030

出　　处：《中国临床药理学杂志》2023年第23期3482-3485,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：通过对1例疑似利伐沙班片致胆固醇结晶栓塞(CCE)的病例进行分析,提示临床药师在药学监护过程中,对于有动脉粥样硬化疾病的患者临床使用利伐沙班等抗凝药物时应警惕CCE的发生,特别是有发生CCE高危因素(如吸烟、高胆固醇血症、高血压、肥胖和糖尿病)的患者,更应加强监护,用药前应询问现病史及既往用药史,并进行风险评估。一旦发生CCE,要及时就诊,积极治疗。Through the analysis of a case of cholesterol crystal embolism(CCE)suspected to be caused by rivaroxaban tablets,it is suggested that clinical pharmacists should be alert to the occurrence of CCE when using anticoagulant drugs such as rivaroxaban in the clinical treatment of patients with atherosclerosis disease,especially for patients with high risk factors(such as smoking,hypercholesterolemia,hypertension,obesity and diabetes)of CCE.Before taking medication,clinical pharmacists should inquire about patients'current medical history and past medication history,and conduct a risk assessment.In case of CCE,timely treatment and curative care are needed.

关 键 词：利伐沙班 抗凝药物 胆固醇结晶栓塞 

分 类 号：R973.2[医药卫生—药品]